Adrenocortical carcinoma (ACC) is an aggressive cancer characterized by poor survival.
Apart from radical surgery, there is a limited range of therapeutic options and mitotane …

Objective Adrenocortical carcinoma (ACC) is a malignancy with a poor prognosis. Many
publications in ACC report on risk factors for a poor outcome; one risk factor studied is …

Two different primary malignancies can arise from the adrenal gland: adrenocortical
carcinoma (ACC) from the adrenal cortex and malignant phaeochromocytoma from the …

Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone-producing
tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with …

Background Adjuvant treatment with mitotane is commonly used after resection of
adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of …

Context: In 2007, a retrospective case-control study provided evidence that adjuvant
mitotane prolongs recurrence-free survival (RFS) in patients with radically resected …

Objective Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course.
Prognostic stratification based on the European Network for the Study of Adrenal Tumours …

Objective: The aim of this Disease State Clinical Review is to provide a practical approach to
patients with newly diagnosed adrenocortical carcinoma, as well as to follow-up and …

Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with an annual incidence
of~ 1 case per million population. Differentiating between ACC and benign adrenocortical …

Background. The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always
been in controversy. We aimed to assess the prognostic benefits of adjuvant mitotane after …